Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Infectious Diseases
Published in: BMC Infectious Diseases 1/2024

Open Access 01-12-2024 | Rickettsia | Review

Gaps and inconsistencies in the current knowledge and implementation of biosafety and biosecurity practices for rickettsial pathogens

Authors: Stuart D. Blacksell, Khanh Kim Le, Artharee Rungrojn, Jantana Wongsantichon, John Stenos, Stephen R. Graves, Nicholas P.J. Day

Published in: BMC Infectious Diseases | Issue 1/2024

Login to get access

Abstract

Introduction

Rickettsia spp. and Orientia spp. are the causes of neglected infections that can lead to severe febrile and systemic illnesses in humans. Implementing proper biosafety practices when handling these pathogens is crucial to ensure a safe and sustainable work environment. It is essential to assess the current knowledge and identify any potential gaps to develop effective measures that minimise the risk of exposure to these pathogens. By doing so, we can establish a comprehensive framework that promotes safety, mitigates hazards, and safeguards the well-being of personnel and the surrounding community.

Methods and results

This review aimed to synthesise and determine the evidence base for biosafety precautions for Rickettsia spp. and Orientia spp. pathogens. Enhancing our understanding of the relative infectious risk associated with different strains of Rickettsia and Orientia spp. requires identifying the infectious dose of these pathogens that can cause human disease. The application of risk groups for Rickettsia and Orientia spp. is inconsistent across jurisdictions. There is also incomplete evidence regarding decontamination methods for these pathogens. With regards to Orientia spp. most of the available information is derived from experiments conducted with Rickettsia spp.

Conclusions

Rickettsia and Orientia spp. are neglected diseases, as demonstrated by the lack of evidence-based and specific biosafety information about these pathogens. In the case of Orientia spp., most of the available information is derived from Rickettsia spp., which may not be appropriate and overstate the risks of working with this pathogen. The advent of effective antibiotic therapy and a better understanding of the true hazards and risks associated with pathogen manipulation should inform decisions, allowing a sustainable and safe work environment.
Appendix
Available only for authorised users
Literature
1.
World Health Organization.: Laboratory biosafety manual, fourth edition. In. Geneva World Health Organization; 2020.
2.
Blacksell SD, Dhawan S, Kusumoto M, Le KK, Summermatter K, O’Keefe J, Kozlovac J, Suhail Almuhairi S, Sendow I, Scheel CM, et al. The Biosafety Research Road Map: the search for evidence to Support practices in Human and Veterinary Laboratories. Appl Biosaf. 2023;28(2):1–8.
3.
Shpynov S, Pozdnichenko N, Gumenuk A. Approach for classification and taxonomy within family Rickettsiaceae based on the formal order analysis. Microbes Infect. 2015;17(11–12):839–44.PubMedCrossRef
4.
Gillespie JJ, Kaur SJ, Rahman MS, Rennoll-Bankert K, Sears KT, Beier-Sexton M, Azad AF. Secretome of obligate intracellular Rickettsia. FEMS Microbiol Rev. 2015;39(1):47–80.PubMedCrossRef
5.
6.
Stewart AG. An update on the Laboratory diagnosis of Rickettsia Spp. Infection. Pathogens (Basel Switzerland). 2021;10(10):1319.PubMed
7.
8.
Kelly DJ, Fuerst PA, Richards AL. Origins, Importance and Genetic Stability of the Prototype Strains Gilliam, Karp and Kato of Orientia tsutsugamushi. In: Tropical Medicine and Infectious Disease vol. 4; 2019.
9.
10.
11.
12.
Mahon SE, Smulowitz PB. Orientia tsutsugamushi (Scrub Typhus) Attack. In: Ciottone’s Disaster Medicine (Second Edition) edn. Edited by Ciottone GR. Philadelphia: Elsevier; 2016: 721–723.
13.
Vincent G. Scrub Typhus and Its Causative Agent, Orientia tsutsugamushi. In: Rickettsiales: Biology, Molecular Biology, Epidemiology, and Vaccine Development edn. Edited by Thomas S; 2016: 329–372.
14.
de la Silva MC, Perez C, Martinez-Valdebenito C, Perez R, Vial C, Stekolnikov A, Abarca K, Weitzel T, Acosta-Jamett G. Eco-epidemiology of rodent-associated trombiculid mites and infection with Orientia spp. in Southern Chile. PLoS Negl Trop Dis. 2023;17(1):e0011051.CrossRef
15.
Varghese GM, Dayanand D, Gunasekaran K, Kundu D, Wyawahare M, Sharma N, Chaudhry D, Mahajan SK, Saravu K, Aruldhas BW, et al. Intravenous doxycycline, azithromycin, or both for severe Scrub Typhus. N Engl J Med. 2023;388(9):792–803.PubMedPubMedCentralCrossRef
16.
Watt G, Chouriyagune C, Ruangweerayud R, Watcharapichat P, Phulsuksombati D, Jongsakul K, Teja-Isavadharm P, Bhodhidatta D, Corcoran KD, Dasch GA, et al. Scrub typhus infections poorly responsive to antibiotics in northern Thailand. Lancet. 1996;348(9020):86–9.PubMedCrossRef
17.
Wangrangsimakul T, Phuklia W, Newton PN, Richards AL, Day NPJ. Scrub Typhus and the misconception of doxycycline resistance. Clin Infect Dis. 2020;70(11):2444–9.PubMedCrossRef
18.
Newton PN, Keolouangkhot V, Lee SJ, Choumlivong K, Sisouphone S, Choumlivong K, Vongsouvath M, Mayxay M, Chansamouth V, Davong V et al. A Prospective, Open-label, Randomized Trial of Doxycycline Versus Azithromycin for the Treatment of Uncomplicated Murine Typhus. Clin Infect Dis 2019, 68(5):738–747.
19.
Blacksell SD, Robinson MT, Newton PN, Ruanchaimun S, Salje J, Wangrangsimakul T, Wegner MD, Abdad MY, Bennett AM, Richards AL, et al. Biosafety and biosecurity requirements for Orientia spp. diagnosis and research: recommendations for risk-based biocontainment, work practices and the case for reclassification to risk group 2. BMC Infect Dis. 2019;19(1):1044.PubMedPubMedCentralCrossRef
20.
21.
Tamrakar SB, Haas CN. Dose-response model of Rocky Mountain spotted fever (RMSF) for human. Risk Anal. 2011;31(10):1610–21.PubMedCrossRef
22.
Gonder JC, Kenyon RH, Pedersen CE Jr. Evaluation of a killed Rocky Mountain spotted fever vaccine in cynomolgus monkeys. J Clin Microbiol. 1979;10(5):719–23.PubMedPubMedCentralCrossRef
23.
Sammons LS, Kenyon RH, Burger GT, Pedersen CE Jr., Spertzel RO. Changes in blood serum constituents and hematologic values in Macaca mulatta with Rocky Mountain spotted fever. Am J Vet Res. 1976;37(6):725–30.PubMed
24.
25.
DuPont HL, Hornick RB, Dawkins AT, Heiner GG, Fabrikant IB, Wisseman CL Jr., Woodward TE. Rocky Mountain spotted fever: a comparative study of the active immunity induced by inactivated and viable pathogenic Rickettsia rickettsii. J Infect Dis. 1973;128(3):340–4.PubMedCrossRef
26.
Maxey KF. Endemic typhus fever of the south-eastern United States: reaction of the guinea pig. Public Health Rep. 1929;44:589–600.CrossRef
27.
McKiel JA, Bell EJ, Lackman DB. Rickettsia Canada: a new member of the typhus group of rickettsiae isolated from Haemaphysalis leporispalustris ticks in Canada. Can J Microbiol. 1967;13(5):503–10.PubMedCrossRef
28.
Bell EJ, Pickens EG. A toxic substance associated with the rickettsias of the spotted fever group. J Immunol. 1953;70(5):461–72.PubMedCrossRef
29.
Bell EJ, Stoenner HG. Immunologic relationships among the spotted fever group of rickettsias determined by toxin neutralization tests in mice with convalescent animal serums. J Immunol. 1960;84:171–82.PubMedCrossRef
30.
31.
Chan TC, Jiang J, Temenak JJ, Richards AL. Development of a rapid method for determining the infectious dose (ID)50 of Orientia tsutsugamushi in a scrub typhus mouse model for the evaluation of vaccine candidates. Vaccine. 2003;21(31):4550–4.PubMedCrossRef
32.
Sunyakumthorn P, Somponpun SJ, Im-Erbsin R, Anantatat T, Jenjaroen K, Dunachie SJ, Lombardini ED, Burke RL, Blacksell SD, Jones JW, et al. Characterization of the rhesus macaque (Macaca mulatta) scrub typhus model: susceptibility to intradermal challenge with the human pathogen Orientia tsutsugamushi Karp. PLoS Negl Trop Dis. 2018;12(3):e0006305.PubMedPubMedCentralCrossRef
33.
Tay ST, Rohani MY, Ho TM, Devi S. Virulence of Malaysian isolates of Orientia tsutsugamushi in mice. Southeast Asian J Trop Med Public Health. 2002;33(3):565–9.PubMed
34.
Nagano I, Kasuya S, Noda N, Yamashita T. Virulence in mice of Orientia tsutsugamushi isolated from patients in a new endemic area in Japan. Microbiol Immunol. 1996;40(10):743–7.PubMedCrossRef
35.
Centers for Disease Control and Prevention. National Institutes of Health: Biosafety in Microbiological and Biomedical Laboratories, vol. 2023, 6th edn; 2020.
36.
37.
38.
Standards Australia. AS/NZS 2243.3.2010 Safety in Laboratories Part 3: Microbiological Safety and Containment. In.
39.
40.
41.
Pathogens and Animal Toxins Act. Government Gaz. 2015;132(Part 80a):9–38.
42.
Londono AF, Mendell NL, Walker DH, Bouyer DH. A biosafety level-2 dose-dependent lethal mouse model of spotted fever rickettsiosis: Rickettsia parkeri Atlantic Rainforest strain. PLoS Negl Trop Dis. 2019;13(6):e0007054.PubMedPubMedCentralCrossRef
43.
Sexton DJ, Gallis HA, McRae JR, Cate TR. Letter: possible needle-associated Rocky Mountain spotted fever. N Engl J Med. 1975;292(12):645.PubMedCrossRef
44.
Vilges de Oliveira S, Faccini-Martínez ÁA, Adelino TER, de Lima Duré AÍ, Barbieri ARM, Labruna MB. Needlestick-Associated Rocky Mountain spotted fever, Brazil. Emerg Infect Dis. 2020;26(4):815–6.PubMedPubMedCentralCrossRef
45.
Oster CN, Burke DS, Kenyon RH, Ascher MS, Harber P, Pedersen CE Jr. Laboratory-acquired Rocky Mountain spotted fever. The hazard of aerosol transmission. N Engl J Med. 1977;297(16):859–63.PubMedCrossRef
46.
Pike RM. Laboratory-associated infections: summary and analysis of 3921 cases. Health Lab Sci. 1976;13(2):105–14.MathSciNetPubMed
47.
Pike RM. Laboratory-associated infections: incidence, fatalities, causes, and prevention. Annu Rev Microbiol. 1979;33:41–66.PubMedCrossRef
48.
Blacksell SD, Robinson MT, Newton PN, Day NPJ. Laboratory-acquired Scrub Typhus and Murine Typhus infections: the argument for a risk-based Approach to Biosafety requirements for Orientia tsutsugamushi and Rickettsia typhi Laboratory activities. Clin Infect Dis. 2019;68(8):1413–9.PubMedCrossRef
49.
Kojima K, Booth CM, Summermatter K, Bennett A, Heisz M, Blacksell SD, McKinney M. Risk-based reboot for global lab biosafety. Science. 2018;360(6386):260–2.ADSPubMedCrossRef
50.
Krishnamoorthi S, Goel S, Kaur J, Bisht K, Biswal M. A review of Rickettsial diseases Other Than Scrub Typhus in India. Trop Med Infect Dis 2023, 8(5).
51.
Wurtz N, Grobusch MP, Raoult D. Negative impact of laws regarding biosecurity and bioterrorism on real diseases. Clin Microbiol Infect. 2014;20:507–15.PubMedCrossRef
52.
Abuelezam NN, Michel I, Marshall BD, Galea S. Accounting for historical injustices in mathematical models of infectious disease transmission: an analytic overview. Epidemics. 2023;43:100679.PubMedPubMedCentralCrossRef
53.
Colby LA, Quenee LE, Zitzow LA. Considerations for infectious Disease Research studies using animals. Comp Med. 2017;67(3):222–31.PubMedPubMedCentral
54.
55.
Zdrodovskii PF, Golinevich HM. The Rickettsial diseases. New York and Oxford: Pergamon; 1960.
56.
Salje J. Cells within cells: Rickettsiales and the obligate intracellular bacterial lifestyle. Nat Rev Microbiol. 2021;19(6):375–90.PubMedCrossRef
57.
Atwal S, Giengkam S, Chaemchuen S, Dorling J, Kosaisawe N, VanNieuwenhze M, Sampattavanich S, Schumann P, Salje J. Evidence for a peptidoglycan-like structure in Orientia tsutsugamushi. Mol Microbiol. 2017;105(3):440–52.PubMedPubMedCentralCrossRef
58.
59.
60.
61.
Tamrakar SB, Huang Y, Teske SS, Haas CN. Dose-response model of murine typhus (Rickettsia typhi): time post inoculation and host age dependency analysis. BMC Infect Dis. 2012;12:77.PubMedPubMedCentralCrossRef
Metadata
Title
Gaps and inconsistencies in the current knowledge and implementation of biosafety and biosecurity practices for rickettsial pathogens
Authors
Stuart D. Blacksell
Khanh Kim Le
Artharee Rungrojn
Jantana Wongsantichon
John Stenos
Stephen R. Graves
Nicholas P.J. Day
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2024
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-024-09151-0

Other articles of this Issue 1/2024

BMC Infectious Diseases 1/2024 Go to the issue

Research

Metagenomic next-generation sequencing of plasma cell-free DNA improves the early diagnosis of suspected infections

Research

Willingness to receive COVID-19 vaccines, associated factors and reasons for not taking a vaccine: a cross sectional study among persons aged 13–80 years in Wakiso, Central Uganda

Research

Herpes zoster (HZ) vaccine coverage and confidence in Italy: a Nationwide cross-sectional study, the OBVIOUS project

Research

Safety analysis of Oseltamivir and Baloxavir Marboxil after market approval: a pharmacovigilance study based on the FDA adverse event reporting system

Research

Spatiotemporal dynamics of cholera hotspots in the Democratic Republic of the Congo from 1973 to 2022

Case Report

Cholangitis with bacteremia due to Pseudomonas nitroreducens in a patient with pancreatic neuroendocrine tumors: a case report
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits